Another day of selling pressure in bio-tech and technology
stocks dragged the benchmarks down on Friday. Also, disappointing
corporate earnings weighed on the markets. However, higher
wholesale prices in March and an increase in preliminary consumer
sentiment in April failed to restrict the day's loss.
AMGEN INC (AMGN): Free Stock Analysis Report
AMAZON.COM INC (AMZN): Free Stock Analysis
BIOGEN IDEC INC (BIIB): Free Stock Analysis
CELGENE CORP (CELG): Free Stock Analysis
FACEBOOK INC-A (FB): Free Stock Analysis
JPMORGAN CHASE (JPM): Free Stock Analysis
LINKEDIN CORP-A (LNKD): Free Stock Analysis
NETFLIX INC (NFLX): Free Stock Analysis
PRICELINE.COM (PCLN): Free Stock Analysis
TRIPADVISOR INC (TRIP): Free Stock Analysis
VERTEX PHARM (VRTX): Free Stock Analysis
YAHOO! INC (YHOO): Free Stock Analysis Report
To read this article on Zacks.com click here.
For a look at the issues currently facing the markets, make sure
to read today's
Ahead of Wall Street
The Dow Jones Industrial Average (DJI) dropped 0.9% to close
Friday's trading session at 16,026.75. The Standard & Poor
(S&P 500) too declined 0.9% to finish at 1,815.69. The
tech-laden Nasdaq Composite Index plunged 1.3% to 3,999.73. The
fear-gauge CBOE Volatility Index (VIX) surged 7.2% to settle at
17.03. Total volume on the New York Stock Exchange was 3.7
billion shares. Advancing stocks were outnumbered by declining
stocks on the NYSE. For 28% stocks that advanced, 69% declined.
The tech-heavy Nasdaq ended in the red zone on Friday, once again
dragged down by declines in bio-tech and technology stocks. The
Nasdaq fell below the key technical level of 4,000 for the first
time since February. For the week, the Nasdaq slumped 3.1%, its
worst weekly percentage drop since July 2012. It also marked
third consecutive week of loss for Nasdaq.
The S&P 500 moved below its 50-day moving average. It is now
almost 4% lower than its April 2 record close of 1,885.52. For
the week, the S&P 500 fell 2.6%. The blue-chip index ended
lower by 2.3% for the week, snapping a three-week rising streak.
Benchmarks declined for the week due to intense selling pressure
in momentum and technology stocks. Separately, discouraging
Chinese trade data unnerved investors. Biopharmaceutical company
Pfizer was a big drag at the start of the week. Shares of Pfizer
were down almost 3% after its breast-cancer drug palbociclib did
well in clinical trials but the overall survival benefits was not
yet revealed to be statistically significant. However, on
Wednesday, benchmarks soared primarily boosted by the encouraging
minutes from the central bank's policy meeting.
Coming back to Friday's events, declines in bio-tech and
technology stocks again had a negative impact on the benchmarks.
Shares of bio-tech companies such as Biogen Idec Inc. (NASDAQ:
), Vertex Pharmaceuticals Incorporated (NASDAQ:
), Amgen Inc. (NASDAQ:
) and Celgene Corporation (NASDAQ:
) plummeted 4.7%, 4.0%, 1.9% and 2.2%, respectively. Overall, the
Health Care Select Sector SPDR (XLV) dropped 0.9%.
Internet and related stocks such as Facebook, Inc. (NASDAQ:
), LinkedIn Corporation (NYSE:
), Yahoo! Inc. (NASDAQ:
) and Google Inc. (NASDAQ:
) decreased 1.1%, 2.5%, 1.6% and 1.9%, respectively. Overall, the
Technology Select Sector SPDR (XLK) was down 1.1%.
Also, stocks from the Consumer Discretionary sector such as
online retailer Amazon.com Inc. (NASDAQ:
), online movie rental company Netflix, Inc. (NASDAQ:
), online travel company TripAdvisor Inc. (NASDAQ:
) and The Priceline Group Inc. (NASDAQ:
) declined 1.7%, 2.4%, 3.6% and 1.8%, respectively. The Consumer
Discretionary Select Sector SPDR (XLY) led the decline among the
S&P 500 sectors. The sector dropped 1.4%. All the 10 sectors
of the S&P 500 ended in the red.
Also, dismal corporate earnings results from JPMorgan Chase &
) had a negative impact on the markets. The financial behemoth
led the decline among the Dow components after its shares plunged
3.7%. The banking giant came out with first quarter earnings of
$1.28 per share that fell short of Zacks Consensus Estimate of
$1.41 per share. This is also significantly lower from the
year-ago number of $1.59 per share.
Meanwhile, shares of Wells Fargo & Company (NYSE:
) rose 0.8% after the company reported first quarter earnings of
$1.05 per share, more than the Zacks Consensus Estimate of 97
cents per share.
On the economic front, the U.S. Bureau of Labor Statistics
reported that the U.S. Producer Price Index (PPI) for finished
goods increased 0.5% in March, more than the consensus estimate
of a rise by 0.1%. This rise in PPI was in sharp contrast to a
fall by 0.1% in February. Rise in cost for service providers like
food and clothing retailers were cited to be the reason for the
rise in U.S. wholesale prices.
Separately, the University of Michigan and Thomson Reuters'
preliminary reading of consumer sentiment increased in April and
touched the highest level in nine months. The gauge was at 82.6
in April, more than the consensus forecast of it rising to